NCT05610189View on ClinicalTrials.gov

Multiple-dose Trial to Determine the Clinical Bioequivalence Between Tavapadon Tablets in Participants With Parkinson's Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

December 15, 2022

Primary Completion Date

December 12, 2023

Study Completion Date

December 17, 2023

Conditions
Parkinson Disease
Interventions
DRUG

Tavapadon

Oral tablets

Trial Locations (6)

30030

Decatur, Georgia, Decatur

32806

Orlando, Florida, Orlando

33024

Hollywood, Florida, Hollywood

33143

South Miami, Florida, South Miami

48334

Farmington Hills, Michigan, Farmington Hills

90720

Los Alamitos, California, Los Alamitos

Sponsors
All Listed Sponsors
lead

Cerevel Therapeutics, LLC

INDUSTRY

NCT05610189 - Multiple-dose Trial to Determine the Clinical Bioequivalence Between Tavapadon Tablets in Participants With Parkinson's Disease | Biotech Hunter | Biotech Hunter